The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer

Adrian G. Murphy; Ronan J. Kelly

doi:10.1016/j.hoc.2017.01.007

The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer

Adrian G. Murphy, Ronan J. Kelly

School of Medicine

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

The connection between inflammation and malignancy has long been recognized in gastric and esophageal cancers. Given the considerable success of immune checkpoint inhibitors in other tumor types, for example, lung cancer and melanoma, much attention is being paid to furthering their role in gastric and esophageal cancers. The Cancer Genome Atlas has provided further details of the molecular heterogeneity of these tumors, which may help predict responsiveness to immune checkpoint inhibitors. This article discusses the rationale for investigating these agents in gastroesophageal cancer and summarizes the relevant clinical trial data and ongoing studies.

Original language	English (US)
Pages (from-to)	485-498
Number of pages	14
Journal	Hematology/Oncology Clinics of North America
Volume	31
Issue number	3
DOIs	https://doi.org/10.1016/j.hoc.2017.01.007
State	Published - Jun 2017

Keywords

Cytotoxic T lymphocyte associated protein −4
Immune checkpoint
Immunotherapy
Nivolumab
Pembrolizumab
Programmed death-1

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.hoc.2017.01.007

Cite this

@article{9441b88bc4f842a59057554a04999a10,

title = "The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer",

abstract = "The connection between inflammation and malignancy has long been recognized in gastric and esophageal cancers. Given the considerable success of immune checkpoint inhibitors in other tumor types, for example, lung cancer and melanoma, much attention is being paid to furthering their role in gastric and esophageal cancers. The Cancer Genome Atlas has provided further details of the molecular heterogeneity of these tumors, which may help predict responsiveness to immune checkpoint inhibitors. This article discusses the rationale for investigating these agents in gastroesophageal cancer and summarizes the relevant clinical trial data and ongoing studies.",

keywords = "Cytotoxic T lymphocyte associated protein −4, Immune checkpoint, Immunotherapy, Nivolumab, Pembrolizumab, Programmed death-1",

author = "Murphy, {Adrian G.} and Kelly, {Ronan J.}",

note = "Funding Information: Commercial and Financial Conflicts of Interest: Dr R.J. Kelly has received grant funding from Bristol-Myers Squibb. Publisher Copyright: {\textcopyright} 2017 Elsevier Inc. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.",

year = "2017",

month = jun,

doi = "10.1016/j.hoc.2017.01.007",

language = "English (US)",

volume = "31",

pages = "485--498",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders",

number = "3",

}

TY - JOUR

T1 - The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer

AU - Murphy, Adrian G.

AU - Kelly, Ronan J.

N1 - Funding Information: Commercial and Financial Conflicts of Interest: Dr R.J. Kelly has received grant funding from Bristol-Myers Squibb. Publisher Copyright: © 2017 Elsevier Inc. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.

PY - 2017/6

Y1 - 2017/6

N2 - The connection between inflammation and malignancy has long been recognized in gastric and esophageal cancers. Given the considerable success of immune checkpoint inhibitors in other tumor types, for example, lung cancer and melanoma, much attention is being paid to furthering their role in gastric and esophageal cancers. The Cancer Genome Atlas has provided further details of the molecular heterogeneity of these tumors, which may help predict responsiveness to immune checkpoint inhibitors. This article discusses the rationale for investigating these agents in gastroesophageal cancer and summarizes the relevant clinical trial data and ongoing studies.

AB - The connection between inflammation and malignancy has long been recognized in gastric and esophageal cancers. Given the considerable success of immune checkpoint inhibitors in other tumor types, for example, lung cancer and melanoma, much attention is being paid to furthering their role in gastric and esophageal cancers. The Cancer Genome Atlas has provided further details of the molecular heterogeneity of these tumors, which may help predict responsiveness to immune checkpoint inhibitors. This article discusses the rationale for investigating these agents in gastroesophageal cancer and summarizes the relevant clinical trial data and ongoing studies.

KW - Cytotoxic T lymphocyte associated protein −4

KW - Immune checkpoint

KW - Immunotherapy

KW - Nivolumab

KW - Pembrolizumab

KW - Programmed death-1

UR - http://www.scopus.com/inward/record.url?scp=85016519504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016519504&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2017.01.007

DO - 10.1016/j.hoc.2017.01.007

M3 - Review article

C2 - 28501089

AN - SCOPUS:85016519504

SN - 0889-8588

VL - 31

SP - 485

EP - 498

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 3

ER -

The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this